PUR 1800

Drug Profile

PUR 1800

Alternative Names: PUR-1800

Latest Information Update: 22 Jun 2017

Price : $50

At a glance

  • Originator RespiVert
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 22 Jun 2017 RespiVert completes a phase IIa trial in Chronic obstructive pulmonary disease (Pulmatrix pipeline, June 2017) before June 2017
  • 13 Jun 2017 Phase-II clinical trials in Chronic obstructive pulmonary disease in United Kingdom (Inhalation) before June 2017
  • 13 Jun 2017 Pulmatrix in-licenses kinase inhibitor compounds from RespiVert
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top